

PTO/SB/08B

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1614
Examiner Name	Brian Yong S. Kwon
Attorney Docket Number	13509.105003US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		2,890,240	06-09-1959	Hamer et al.	
		3,235,583	02-15-1966	Edmunds	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code - Number - Kind Code (If known)				
		WO 2000/066130	11-09-2000	Sanofi-Synthelabo		
		HU P1991 03745 (HU 211993)	12-02-1991	Gedeon Richter Chemical Works, Ltd.	English abstract only	
		HU P1991 03746 (HU 211729)	12-02-1991	Gedeon Richter Chemical Works, Ltd.	English abstract only	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 501.04. Enter Office that issued the document, by the loc-letter code (WIPO Standard ST 3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22315-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22315-1450.

PTO/SB/08B

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/600,266
Filing Date	June 20, 2003
First Named Inventor	Fumitoshi Asai
Art Unit	1614
Examiner Name	Brian Yong S. Kwon
Attorney Docket Number	13509.105003US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Asai et al., "Antithrombotic and Antiplatelet Effects of CS-747, A Novel P2Y Antagonist," Thromb. Haemost. 1999 (Supp) p. 829	
		Born et al., "Aspirin versus clopidogrel: the wrong question?" The Lancet, 349, 1997, p. 806-7, March 15, 1997	
		Kolansky et al., "Combination Therapy with Clopidogrel and Aspirin After Coronary Stenting," Catheter Cardiovasc Interv., vol. 50, 276-279 (2000)	
		Leon et al., "A Clinical Trial Comparing Three Antithrombotic-drug Regimens After Coronary-Artery Stenting," New England Journal of Medicine, vol. 339, no. 23, pp. 1665-1671, December 3, 1998.	
		Martindale, "The Extra Pharmacopeia," 31st edition, pp. 17-22, 1996	
		Moussa, "Effectiveness of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin in Preventing Stent Thrombosis After Coronary Stent Implantation," Circulation, 99, 2364-2366, May 11, 1999.	
		Müller et al., "A Randomized Comparison of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin After the Placement of Coronary-Artery Stents," Circulation; vol. 101, pp. 590-593, 2000	
		Press Release of Eli Lilly and Sankyo of December 21, 2000, Chemie.DE Information Service	
		Quinn et al., "Ticlopidine and Clopidogrel," Circulation, vol. 100, 1667-1672, Oct. 12, 1999.	
		Rupprecht et al., "Comparison of Antiplatelet Effects of Aspirin, Ticlopidine, or Their Combination After Stent Implantation," Circulation, 1998, 97, pp. 1046-1052	
		Savi et al., "Identification and Biological Activity of the Active Metabolite of Clopidogrel," Thromb. Haemost, 2000, 84, pp. 891-896	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Notice to Inventors of USPTO Patent Documents at appropriate date or MPEP 901.04. Error Office that issued the document by the two-letter code (WIPO Standard ST 3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ¹ Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST. If possible, Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain, or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 422 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	3	of	3
-------	---	----	---

Complete if Known

Application Number	10/600.26
--------------------	-----------

June 20, 2003

First Named Inventor	Fumitoshi Asai
----------------------	----------------

Art Unit	1614
----------	------

Examiner Name	Brian Yong S. Kwon
---------------	--------------------

Attorney Docket Number	13509.105003US
------------------------	----------------

NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner
Signature

~~/Brian Yong Kwon/~~

Date
Considered

03/14/2010

[illegible]

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.K./